The AHA yesterday voiced support for the Opioid Treatment Access Act (H.R. 6279), bipartisan legislation that would take steps to facilitate patients’ access to methadone treatment for opioid use disorder. The bill would direct the Substance Abuse and Mental Health Services Administration to study the impact of certain flexibilities implemented during the COVID-19 public health emergency to enhance access to methadone treatment services and reduce stigma; allow patients to receive one-month supplies of methadone after two years of continuous treatment; permit pharmacies to dispense methadone; and codify regulations that allow opioid treatment programs to operate mobile medication components without separate registration.

Related News Articles

Headline
Three retiring members of Congress — Brad Wenstrup, R-Ohio, Larry Bucshon, R-Ind., and Dan Kildee, D-Mich. — engaged in a genial conversation that covered the…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
Stacey Hughes, AHA’s executive vice president for government relations and public policy, discussed key messages that hospital and health system leaders should…
Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
President Biden March 24 signed legislation funding the rest of the federal government through Sept. 30, including Department of Health and Human Services…
Headline
The House and Senate Appropriations committees March 20 released the Further Consolidated Appropriations Act of 2024, legislation that would fund all remaining…